- Pfizer Inc, which has been on a hot streak with three recent approvals of cancer drugs, stumbled on Monday, saying it was halting a late-stage trial of a drug for aggressive non-Hodgkin lymphoma after independent monitors found it was not likely to improve survival.
FRANKFURT - Bayer said extended use of its experimental riociguat pill to treat a life-threatening form of high blood pressure in the lungs was shown to be safe and effective in a prolonged trial.
NEW YORK (Reuters Health) - The importance of health literacy hit home for Lisa Gualtieri when a Cambodian refugee diagnosed with cancer asked her to act as a patient advocate.
NEW YORK (Reuters Health) - Men who get an older and less costly form of radiation after their cancerous prostates are removed fare just as well as men who get a new and expensive type of radiation, according to a new study.
NEW YORK (Reuters Health) - Older men with other illnesses may not live long enough to benefit from aggressive prostate cancer treatments, such as prostate removal or radiation, and they'd have to live with their side effects, says a new study.
LONDON - British farmers will be the first in Europe to get a vaccine against Schmallenberg virus, a new livestock disease that hit the continent in 2011.
- Farms in two of the nation's leading pork producing states have tested positive for the potentially fatal porcine epidemic diarrhea virus (PEDV), U.S. pork industry veterinarian official said Monday.
- Generic drugmaker Actavis Inc, itself a recent takeover target, said on Monday it would buy specialty pharmaceutical company Warner Chilcott Plc for $5 billion in stock to expand its branded drug portfolio, lower taxes and increase profits.
LONDON - Britain launched a research program on Monday that should eventually allow all cancer patients to have access to the kind of genetic analysis that led Hollywood star Angelina Jolie to decide to undergo a double mastectomy.
WASHINGTON - Merck & Co's experimental insomnia drug suvorexant appears generally effective, according to reviewers at the U.S. Food and Drug Administration, but they questioned the company's proposed dosing levels.